Early Stage TNBC Neoadjuvant treatment of early stage TNBC aims to reduce the extent of surgical excision for operable tumors or convert inoperable tumors to operable tumors. The treatment goal is to attain a pathological complete response (pCR), defined as the eradication of invasive cancer from ...
It is generally agreed that an effective strategy for targeting melanoma BrM involves converting the brain’s immunologically ‘cold’ environment into an immunoreactive TME54,55. A retrospective analysis of more than 2700 patients with stage 4 melanoma enrolled in the US National Cancer Database betw...
Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments View More Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice View More Identifying Health...
Beyond PD-1/PD-L1 inhibitors, other immunotherapies for TNBC are being explored and validated. CTLA-4 inhibitors, another class of ICIs, have the potential to activate or restore T-cell function in TNBC. Pabolizumab is believed to be effective in the adjuvant treatment of early TNBC. A pre...
Community Oncology Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care View More Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments View More Next-Generation Endocrin...
Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Tennessee View More Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Kansas View...
The gene-editing tool known as CRISPR may eventually enable oncology investigators to create methods for killing tumors directly, but thus far, the focus is on enhancing forms of immunotherapy already in clinical practice.
Stereotactic ablative radiotherapy (SABR) is standard-of-care for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC), however the risk of systemic recurrences remains high. Here the authors report the results of a phase I study testing the addition of atezolizumab (...
Beyond single-agent chemotherapy, few effective treatment options are available for metastatic triple-negative breast cancer (TNBC), according to Candace Mainor, MD, but several approaches comprised of immunotherapy, antibody-drug conjugates (ADCs), and PARP inhibitors are shifting standards of care and...
may serve as a stratagem to counteract immune pressures during the effector stage, with a selective affinity for PD-1 + CD8 + T cells [55]. The PD-L1 adorning the surface of cancer cell EVs engages with PD-1 receptors on CD8 + T cells, resulting in the impediment of ...